20 results about "Diabetes Therapy" patented technology

Disclosed herein are apparatuses and methods that can provide a delayed bolus calculator for use in closed loop diabetes therapy that can account for additional factors not taken into account in regular meal bolus calculations when a user wants to deliver a meal bolus a period of time after a meal was consumed. A delayed bolus calculator can enable the user to enter a period of time since the meal was consumed in addition to the number of carbohydrates consumed in a meal. This enables the system to account for the amount of increased insulin from the closed loop algorithm in response to the meal and / or the time since the meal to ensure that the risk of hypoglycemia is mitigated while still reducing hyperglycemia.

A blood based diabetes treatment protocol AI platform includes an AI platform database which includes demographics, such as age, gender, height, weight, occupation, ethnicity, social habits, medications and family history, medical symptoms, and specialized bloodwork panel of a patient; Wherein the AI platform is configured for Analyzing bloodwork and demographics to categorize a patient, and for Assigning treatment regimen including retesting, optional supplementation and medication and for Assigning at least one phase of a three phase diet regimen; and Wherein the AI platform is configured for prediction of the patient weight loss and lowering of Type 2 diabetes and prediabetes markers within a set time period on the protocol.

Devices, systems, and techniques for guiding therapy delivery to a diabetes patient is described. Some devices, systems, and techniques proactively monitor the patient's food consumption and (if needed) adapt the patient's diabetes therapy accordingly. In one example, a system comprises one or more sensors configured to capture a representation of the object, and processing circuitry configured to determine data corresponding to the representation of the object, wherein the data comprises information identifying the object as a particular food item; generate food item information based on the information identifying the object as the particular food item, wherein the food item information comprises at least one of nutrition information or volume information of the particular food item, generate therapy information for the patient based on the food item information, and output content indicative of at least one of the therapy information or the food item information.

The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said individual, and / or at least three matched pre-prandial glucose measurement values and postprandial glucose measurement values at the same meal from said individual. Further contemplated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instructions, when executed by the processing unit, causes the processing unit to perform the computer-implemented method of the present invention.

Describes devices, systems, and techniques for controlling the delivery of diabetes therapies. In one example, the system includes: a wearable device configured to generate user activity data associated with a user's arm; and one or more processors configured to: identify, based on the user activity data, at least one gesture indicative of preparing an insulin injection using an injection device; generate, based on the at least one identified gesture, information indicative of at least one of an amount or type of an insulin dose in the insulin injection performed by the injection device; compare the generated information with a standard for an appropriate insulin injection; and, based on the comparison, output information indicative of whether the standard is met.

Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.

Techniques for data analysis and user guidance are provided for determining and providing one or more therapies to a user based on where the user is or will be in their menstrual cycle. In certain embodiments, a method of personalizing diabetes therapy based on information related to a user's menstrual cycle is provided. The method includes measuring blood glucose measurements of the user using a glucose monitoring system. The method also includes receiving information related to the user's menstrual cycle. The method further includes determining a therapy for the user to achieve a target blood glucose during a sub-phase or phase of the user's menstrual cycle based on at least one of historical data associated with the user and historical data associated with a stratified group.

The present disclosure is based in part on research related to novel tolerogenic peptides derived from proteins expressed by pancreatic cells, developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed are tolerogenic peptides that can bind to MHC class II molecules without relying on antigen processing, and are derived from proteins expressed by pancreatic cells, for use in the treatment of type 1 diabetes.

The application discloses a multi-modal diabetes dynamic treatment effect evaluation method, relates to the technical field of data processing, and unifies a time axis and marks reliability for multi-source data through an adaptive interpolation and alignment strategy; peak values and abnormal fluctuations within one to two weeks are detected and recognized based on a short-term window, a short-term change amount and a risk prompt are generated; a multi-layer attention or a Transformer is used to fuse data on a monthly scale, comprehensive long-term treatment effect indexes and key inflection points are extracted; short-term quantitative results and long-term indexes are brought into a multi-target reward mechanism through a continuous learning and interactive real-time feedback module, model parameters are iterated online, and clinical intervention suggestions are output; external events are quantitatively marked, and identification and response to sudden situations are strengthened through a bias injection mode. High-quality integration of multi-source heterogeneous data, short-term and long-term multi-level analysis are realized, and the precision and timeliness of diabetes dynamic monitoring and intervention are significantly improved.

Devices, systems, and techniques for controlling delivery of diabetes therapy are described. In one example, a system includes a wearable device configured to generate user activity data associated with an arm of a user; and one or more processors configured to: identify, based on the user activity data, at least one gesture indicative of preparing an insulin injection with an injection device; generating information indicative of at least one of an amount or type of insulin dose in the insulin injection by the injection device based on the at least one recognized gesture; comparing the generated information to a criterion for an appropriate insulin injection; and based on the comparison, outputting information indicating whether the criteria are met.

The application discloses an intelligent self-adaptive ablation system, an ablation catheter and a method for type 2 diabetes treatment, and belongs to the technical field of medical devices. The system comprises an intelligent control host and an electrode unit library. The intelligent control host integrates a main control processor, a motion prediction decision unit, an intelligent driving control module and an intelligent energy control module. The electrode unit library comprises a plurality of electrode units with different structures. The main control processor and the motion prediction decision unit automatically select an optimal electrode unit based on the duodenal cavity tract anatomical form obtained by a sensing component. The intelligent driving control module receives instructions to drive the selected electrode unit to adapt to the cavity environment. The intelligent energy control module provides controlled ablation energy to the electrode unit. Through the "sensing-decision-execution" closed loop, the application realizes self-adaptive and precise ablation treatment in the duodenal dynamic environment, thereby solving the problems of passive control strategy and lack of prospective compensation in the prior art which depend on a single electrode form.

The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26] and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention relates to the technical field of biological medicine and gene therapy, in particular to a nucleic acid delivery system for targeting pancreatic beta cells and application of the nucleic acid delivery system. The composition comprises a nano-composite formed by a cationic polymer modified by a targeting ligand and siRNA (small interfering Ribonucleic Acid), the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is the siRNA of the target DYRK1A (DYRK1A). The invention provides a brand-new pancreatic beta cell targeted delivery platform for gene therapy of type 2 diabetes mellitus. The platform realizes beta cell function regeneration by accurately regulating and controlling DYRK1A gene expression, has targeting property, safety and high efficiency, and provides a new strategy with wide clinical application prospect for diabetes treatment.

The invention provides a diabetes therapy using a traditional Chinese medicine compound to regulate glycolipid metabolism, and belongs to the technical field of medicine.The diabetes therapy using the traditional Chinese medicine compound to regulate glycolipid metabolism is characterized in that the traditional Chinese medicine compound is composed of radix astragali, ginseng, coptis chinensis and other medicinal materials, and the weight ratio of the medicinal materials is determined according to clinical trials; the medicinal materials are soaked, decocted, filtered and concentrated to prepare decoction, or can be processed into pills, powder, capsules and the like, the taking dosage is determined according to the illness state and the physical condition of a patient, the treatment period is 3-6 months, and the scheme is adjusted according to the change of indexes such as fasting blood glucose, postprandial 2-hour blood glucose, glycosylated hemoglobin and blood fat in the treatment period. The therapy can adjust glycolipid metabolism in a multi-target mode, personalized treatment is achieved, the side effect of the traditional Chinese medicine compound is small, different dosage forms meet various requirements, insulin resistance can be effectively improved, the risk of diabetic complications is reduced, and a safer and more effective treatment choice is provided for diabetic patients.

The invention discloses an intelligent self-adaptive ablation system, ablation catheter and method for treating type 2 diabetes mellitus, and belongs to the technical field of medical instruments. The system comprises an intelligent control host and an electrode unit library, wherein the intelligent control host integrates a main control processor, a motion prediction decision unit, an intelligent driving control module and an intelligent energy control module; the electrode unit library comprises a plurality of electrode units with different structures. The main control processor and the motion prediction decision-making unit automatically select the optimal electrode unit based on the duodenal cavity anatomical form obtained by the sensing assembly; the intelligent driving control module receives an instruction to drive the selected electrode unit to adapt to the cavity environment; the intelligent energy control module provides controlled ablation energy to the electrode unit. The self-adaptive and accurate ablation treatment in a duodenum dynamic environment is realized through a'sensing-decision-execution 'closed loop, so that the problems of dependence on a single electrode form, passive control strategy and lack of prospective compensation in the prior art are solved.

Provided herein, in some aspects, are methods for preventing or treating diabetes in a subject, the method comprising assaying a genomic sample obtained from the subject for an intergenic variant located in a region between a C2 calcium-dependent domain containing 4A gene (C2CD4A) and a C2 calcium-dependent domain containing 4B gene (C2CD4B), and when the intergenic variant is present in the genomic sample, administering to the subject a therapy for diabetes. Also provided herein are rodent cells homozygous for a C2cd4a mutation and / or homozygous for a C2cd4h mutation, and methods for producing the rodent cells.

The invention provides an efficient screening method of immobilized alpha-amylase and a corn stigma source alpha-amylase inhibitor based on a magnetic carrier, and mainly solves the technical problems that the existing diabetes drugs have obvious side effects and the screening efficiency of natural active ingredients is low. In order to solve the problem of drug tolerance generally existing in treatment of type 2 diabetes mellitus, a magnetic MOF carrier is used in the scheme, and efficient immobilization of alpha-amylase is realized through a synergistic strategy of amino functional surface modification and glutaraldehyde crosslinking. The immobilized enzyme system and ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF / MS) form a combined platform, and a three-stage analysis process of magnetic enzyme reaction-precise molecular weight screening-MS / MS structure confirmation is established. Compared with the traditional tedious screening period, the technology can complete the discovery and confirmation of the active components in a short time, and provides an efficient and industrialized solution for the discovery of the plant-derived hypoglycemic lead compound.

Techniques are provided for data analysis and user guidance for determining and providing one or more treatments to a user based on a location of the user in or to be in its menstrual cycle. In certain embodiments, a method of personalizing diabetes treatment based on information related to a user's menstrual cycle is provided. The method includes measuring a blood glucose measurement of a user using a glucose monitoring system. The method also includes receiving information related to a menstrual cycle of the user. The method further includes determining a treatment of the user based on at least one of historical data associated with the user and historical data associated with the hierarchical group to achieve a target blood glucose during a sub-stage or stage of a menstrual cycle of the user.

Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.